LarotrectinibAcquired drug resistance and liver toxicity following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1978卷 / 1期

关键词：

D O I：

10.1007/s40278-023-47588-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：221 / 221

相关论文

共 50 条

[31] TocilizumabNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2021, 1853 (1) : 446 - 446
[32] GlibenclamideHypoglycaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1857 (1) : 162 - 162
[33] NivolumabPsoriasis following an off-label use: case report
[J]. Reactions Weekly, 2018, 1717 (1) : 214 - 214
[34] PrednisoloneInefficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1910 (1) : 405 - 405
[35] SunitinibCardiomyopathy following off-label use: case report
[J]. Reactions Weekly, 2023, 1971 (1) : 240 - 240
[36] CyclophosphamideMyelosuppression following off-label use: case report
[J]. Reactions Weekly, 2020, 1835 (1) : 116 - 116
[37] RisperidonePancreatitis following off-label use: case report
[J]. Reactions Weekly, 2022, 1934 (1) : 378 - 378
[38] SirolimusNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2023, 1960 (1) : 394 - 394
[39] DenosumabHypocalcaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1923 (1) : 178 - 178
[40] Cefepime/piperacillin/tazobactamDevelopment of drug resistance and off-label use: case report
[J]. Reactions Weekly, 2023, 1943 (1) : 192 - 192

← 1 2 3 4 5 →